Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,442
-94.25%
|
$407,238
$39.09 P/Share
|
|
Feb 19
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,184
-5.19%
|
$202,176
$39.08 P/Share
|
|
Feb 19
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,734
-5.33%
|
$106,626
$39.07 P/Share
|
|
Feb 18
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,847
+2.34%
|
-
|
|
Feb 18
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+50.0%
|
-
|
|
Feb 18
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,442
+50.0%
|
-
|
|
Feb 18
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+18.06%
|
-
|
|
Feb 18
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,354
+24.43%
|
-
|
|
Jan 11
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,896
-1.79%
|
$1,298,776
$31.85 P/Share
|
|
Jan 11
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,638
-95.07%
|
$608,778
$31.86 P/Share
|
|
Jan 11
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
19,638
-93.95%
|
$608,778
$31.86 P/Share
|
|
Jan 11
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,684
-19.74%
|
$309,888
$32.02 P/Share
|
|
Jan 11
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,367
-10.05%
|
$135,377
$31.87 P/Share
|
|
Jan 08
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
41,896
+3.44%
|
-
|
|
Jan 08
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,638
+50.0%
|
-
|
|
Jan 08
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,638
+50.0%
|
-
|
|
Jan 08
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Bona fide gift
|
Direct |
350
-100.0%
|
-
|
|
Jan 08
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,948
+29.92%
|
-
|
|
Jan 08
2021
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,092
+37.47%
|
-
|
|
Jan 04
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
48,341
-1.04%
|
$1,498,571
$31.17 P/Share
|
|
Jan 04
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,160
-90.18%
|
$500,960
$31.17 P/Share
|
|
Jan 04
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
15,810
-84.25%
|
$490,110
$31.17 P/Share
|
|
Jan 03
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,341
+2.82%
|
-
|
|
Jan 03
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,160
+50.0%
|
-
|
|
Jan 03
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,160
+50.0%
|
-
|
|
Dec 31
2020
|
Christopher D Alafi Director |
BUY
Grant, award, or other acquisition
|
Direct |
495
+0.14%
|
$15,345
$31.8 P/Share
|
|
Dec 31
2020
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
495
+0.8%
|
$15,345
$31.8 P/Share
|
|
Dec 31
2020
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
222
+2.68%
|
$6,882
$31.8 P/Share
|
|
Dec 31
2020
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
471
+0.49%
|
$14,601
$31.8 P/Share
|
|
Dec 18
2020
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+2.88%
|
$68,000
$2.74 P/Share
|
|
Dec 17
2020
|
Joel S Marcus |
BUY
Bona fide gift
|
Indirect |
28,379
+29.59%
|
-
|
|
Dec 17
2020
|
Joel S Marcus |
SELL
Bona fide gift
|
Direct |
28,379
-100.0%
|
-
|
|
Nov 17
2020
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
79,425
-97.63%
|
$2,144,475
$27.78 P/Share
|
|
Nov 17
2020
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+48.57%
|
$975,000
$13.86 P/Share
|
|
Nov 11
2020
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
28,034
-100.0%
|
$700,850
$25.41 P/Share
|
|
Nov 11
2020
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.98%
|
$60,000
$3.05 P/Share
|
|
Nov 10
2020
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-2.17%
|
$1,300,000
$26.45 P/Share
|
|
Nov 04
2020
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-4.12%
|
$1,250,000
$25.0 P/Share
|
|
Oct 16
2020
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,792
-19.45%
|
$176,592
$26.8 P/Share
|
|
Oct 15
2020
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,448
+27.81%
|
-
|
|
Sep 30
2020
|
Christopher D Alafi Director |
BUY
Grant, award, or other acquisition
|
Direct |
613
+0.18%
|
$15,325
$25.66 P/Share
|
|
Sep 30
2020
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
584
+0.61%
|
$14,600
$25.66 P/Share
|
|
Sep 30
2020
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
613
+1.0%
|
$15,325
$25.66 P/Share
|
|
Sep 30
2020
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
276
+3.4%
|
$6,900
$25.66 P/Share
|
|
Jun 18
2019
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
14,189
+9.75%
|
-
|
|
Jun 18
2019
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
14,189
+18.09%
|
-
|